Chemistry: molecular biology and microbiology – Apparatus – Including condition or time responsive control means
Patent
1996-12-05
1998-06-09
Beisner, William H.
Chemistry: molecular biology and microbiology
Apparatus
Including condition or time responsive control means
4352866, 4352974, 435 3, 435400, 4352941, C12M 306, C12N 500
Patent
active
057632618
ABSTRACT:
A cell growing device for in vitro cell population growth includes at least one hollow fiber cartridge having a plurality of capillaries at least one of which is selectively permeable. The flow of media out of a lumen of the cartridge is substantially blocked off thereby forcing media flowing into the lumen via an inflow opening to permeate across the capillaries of the cartridge and into the extracapillary space thereof.
REFERENCES:
patent: 3883393 (1975-05-01), Knazek et al.
patent: 4266026 (1981-05-01), Breslau
patent: 4690915 (1987-09-01), Rosenberg
patent: 4722902 (1988-02-01), Harm et al.
patent: 4804628 (1989-02-01), Cracauer et al.
patent: 4889812 (1989-12-01), Guinn et al.
patent: 5057423 (1991-10-01), Hiserodt et al.
patent: 5126132 (1992-06-01), Rosenberg
patent: 5199942 (1993-04-01), Gillis
patent: 5229115 (1993-07-01), Lynch
patent: 5424209 (1995-06-01), Kearney
patent: 5627070 (1997-05-01), Gruenberg
G. DelPrete, A. Tiri, M. DeCarli, S. Mariotti, A. Pincheara, I. Chretien, S. Romagnani, and M. Ricci, High Potential to Tumor Necrosis Factor X (INF-x) Production of Thyroid-Infiltrating T Lymphocytes in Hashimoto's Thyroiditis: A Peculiar Feature of Destructive Thyroid Autoimmunity, Autoimmunity, 4:267 (1989).
E.J. Davis, D.O. Cooney, and R. Chang, Mass Transfer Between Capillary Blood and Tissues, Chem. Eng. J., 7:213 (1974).
J. Igietseme, K. Ramsey, D. Magee, D. Williams, J. Kincy, and R. Rank, Resolution of Marine Chlamydial Genital Infection by the Adoptive Transfer of a Biovar-Specific, TH1 Lymphocyte Clone, Regional Immunol., 5:317 (1993).
T. Whiteside, E. Elder, O. Moody et al., Generation and Characterization of Ex-Vivo Propagated Autologous CDST Cells Used for Adoptive Immunotherapy of Patients Infected With Human Immunodeficiency Virus, Blood, 81:2085 (1993).
N. Klimas, R. Patarca, J. Walling, R. Garcia, V. Mayer, D. Moody, T. Okarma and M. Fletcher, Clinical and Immunological Changes in AIDS Patients Following Adoptive Therapy with Activated Autologous CD8 T Cells and Interleukin-2 Infusion, Aids, vol. 8, pp. 1073-1081, 1994.
S. Riddell, M. Gilbert and P. D. Greenberg, CD8.sup.+ Cytotoxic T Cell Therapy of Cytomegalovirus and HIV Infection, Current Opinion in Immunology, vol. 5, pp. 484-491, 1993.
D. Torpey III, X. Huang, J. Armstrong, M. Ho, T. Whiteside, D. McMahon, G. Pazin, R. Herberman, P. Gupta, C. Tripoli, D. Moody, T. Okarma, E. Elder, and C. Rinaldo, Jr., Effects of Adoptive Immunotherapy with Autologous CD8.sup.+ T Lymphocytes on Immunologic Parameters: Lymphocyte Subsets and Cytotoxic Activity, Clinical Immunology and Immunopathology, vol. 68, No. 3, pp. 263-272, Sep. 1993.
M. Ho, J. Armstrong, D. McMahon, G. Pazin, X. Li Huang, C. Rinaldo, T. Whiteside, C. Tripoli, G. Levine, D. Moody, T. Okarma, E. Elder, P. Gupta, A Phase 1 Study of Adoptive Transfer of Autologous CD8.sup.+ T Lymphocytes in Patients With Acquired Immunodeficiency Syndrome (AIDS)-Related Complex or Aids, Blood, vol. 81, No. 8, pp. 2093-2101, Apr. 15, 1993.
S. Riddell, K. Watanabe, J. Goodrich, C. Li, M. Agha, P. Greenberg, Restoration of Viral immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones, Science, vol. 257, pp. 238-241. Jul. 10, 1992.
L. Romani, S. Mocci, C. Bietta, L. Lanfaloni, P. Puccetti, and F. Bistoni, Th1 and Th2 Cytokine Secretion Patterns in Murine Candidiasis: Association of Th1 Responses with Acquired Resistance, Infection and Immunity, vol. 54, No. 12, pp. 4647-4654, Dec. 1991.
A. Saoudi, J. Kuhn, K. Huygen, Y. Kozak, T. Velu, M. Goldman, P. Druet, and B. Bellon, TH2 Activated Cells Prevent Experimental Autoimmune Uveoretinitis, a TH1-Dependent Autoimmune Disease, Eur. J. Immunol., vol. 23, pp. 3096-3103, 1993.
E. Grimm, A. Mazumder, H. Zhang, and S. Rosenberg, Lymphokine-Activated Killer Cell Phenomenon, Journal of Experimental Medicine, vol. 155, pp. 1823-1841, Jun. 1982.
S. Rosenberg, M. Lotze, L. Muul, A. Chang, F. Avis, S. Leitman, W. Linehan, G. Robertson, R. Lee, J. Rubin, C. Seipp, C. Simpson, and D. White, A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone, The New England Journal of Medicine, vol. 316, No. 15, pp. 889-897, Apr. 9, 1987.
S. Rosenberg, M. Lotze, L. Muul, S. Leitman, A. Chang, S. Ettinghausen, Y. Matory, J. Skibber, E. Shiloni, J. Vetto, C. Seipp, C. Simpson, and C. Reichert, Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer, The New England Journal of Medicine, vol. 313, No. 23, pp. 1485-1490, Dec. 5, 1985.
J. Eastcott, K. Yamashita, M. Taubman, Y. Harada, D. Smith, Adoptive Transfer of Cloned T Helper Cells Ameliorates Periodontal Disease in Nude Rats, Oral Microbiology and Immunology, vol. 9, pp. 284-289, 1994.
P. Thygesen, L. Brandt, T. Jorgensen, H. Christensen, H. Hougen, E. Jensen, J. Rygaard, Immunity to Experimental Salmonella Typhimurium Infections in Rats, APMIS, vol. 102, pp. 489-494, 1994.
T. Utsugi, M. Nagata, T. Kawamura, and J. Yoon, Prevention of Recurrent Diabetes in Syngenic Islet-Translanted Nod Mice by Transfusion of Autoreactive T Lymphocytes, Transplanation, vol. 57, 1799-1804, No. 12, pp. 1799-1804, Jun. 1994.
F. Powrie, R. Correa-Oliveira, S. Mauze, and R. Coffman, Regulatory Interactions Between CD45RB.sup.high and CD45RB.sup.low CD4+ T Cells Are Important for the Balance Between Protective and Pathogenic Cell-mediated Immunity, J. Exp. Med., vol. 179, pp. 589-600, Feb. 1994.
R. Dillman, R. Oldham, K. Tauer, D. Orr, N. Barth, G. Blumenschein, J. Arnold, R. Birch, and W. West, Continuous Interleukin-2 and Lymphokine-Activated Killer Cells for Advanced Cancer: A National Biotherapy Study Group Trial, Journal of Clinical Oncology, vol. 9, No. 7, pp. 1233-1240, Jul. 1991.
J. Thompson, K. Shulman, M. Benyunes, C. Lindgren, C. Collins, P. Lange, W. Bush, Jr., L. Benz, and A. Fefer, Prolonged Continuous Intravenous Infusion Interleukin-2 and Lymphokine-Activated Killer-Cell Therapy for Metastatic Renal Cell Carcinoma, Journal of Clinical Oncology, vol. 10, No. 6, pp. 960-968, Jun. 1992.
K. Foon, P. Walther, Z. Bernstein, L. Vaickus, R. Rahman, H. Watanabe, J. Sweeney, J. Park, D. Vesper, D. Russell, R. Walker, T. Darrow, T. Linna, D. Farmer, W. Lynch, Jr., R. Huben, and M. Goldrosen, Renal Cell Carcinoma Treated with Continuous-Infusion Interleukin-2 with Ex Vivo-Activated Killer Cells, Journal of Immunotherapy, vol. 11, No. 3, pp. 184-190, 1992.
M. Koretz, D. Lawson, M. York, S. Graham, D. Murray, T. Gillespie, D. Levitt, and K. Sell, Randomized Study of Interleukin 2 (IL-2) Alone vs IL-2 Plus Lymphokine-Activated Killer Cells for Treatment of melanoma and Renal Cell Cancer, Arch Surg, vol. 126, pp. 898-903, Jul. 1991.
P. Sedlmayr, H. Rabinowich, E. Elder, M. Ernstoff, J. Kirkwood, R. Herberman, and T. L. Whiteside, Depressed Ability of Patients with Melanoma or Renal Cell Carcinoma to Generate Adherent Lymphokine-Activated Killer Cells, Journal of Immunotherapy, vol. 10, No. 5, pp. 336-346, 1991.
M. Sacchi, D. Vitolo, P. Sedlmayr, H. Rabinowich, J. Johnson, R. Herberman, and T. Whiteside, Induction of Tumor Regression in Experimental Model of Human and Neck Cancer by Human A-Lak Cells and IL-2, Int. J. Cancer, vol. 47, pp. 784-791, 1991.
S. Rosenberg, B. Packard, P. Aebersold, D. Solomon, S. Topalian, S. Toy, P. Simon, M. Lotze, J. Yang, C. Seipp, C. Simpson, C. Carter, St. Bock, D. Schwartzentruber, J. Wei, and D. White, Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma, The New England Journal of Medicine, vol. 319, No. 25, pp. 1676-1680, Dec. 22, 1988.
R. Dillman, R. Oldham, N. Barth, R. Cohen, D. Minor, R. Birch, J. Yannelli, J. Maleckar, A. Sferruzz, J. Arnold, and W. West, Continuous Interleukin-2 and Tumor-Infiltrating Lymphocytes as Treatment of Advanced Melanoma, Cancer, vol. 68, pp. 1-8, Jul. 1, 1991.
S. Huet, H. Wakasugi, G. Sterkers, J. Gilmour, T. Tursz, L. Boumsell, and Cells in Activating Restin
Beisner William H.
CellTherapy, Inc.
LandOfFree
Cell growing device for in vitro cell population expansion does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cell growing device for in vitro cell population expansion, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cell growing device for in vitro cell population expansion will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2198064